You are here: Industry Insights > Bcl-2

News List

Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months PR Newswire
December 10, 2024
Ascentage Pharma (6855.HK) today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax , in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis.
Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax PR Newswire
December 10, 2024
Ascentage Pharma (6855.HK) today announced that it has released the latest clinical data of lisaftoclax (APG-2575) as a monotherapy or in combinations in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety PR Newswire
December 10, 2024
Ascentage Pharma today announced that it has released the follow-up safety and efficacy data of the company's investigational Bcl-2 selective inhibitor.
Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA PR NEWSWIRE
November 22, 2024
Ascentage Pharma announced that a NDA for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575)has been accepted and recommended the Priority Review designation CDE and NMPA.